BERN. Detailed results from two phase III trials show remibrutinib beat an older Sanofi drug and spared the liver. Analysts had pencilled in a bigger drop in relapses, and Roche’s fenebrutinib still looks stronger on that measure. The proposal lands as households open their premium letters and parliament returns to its most reliable battleground.
For patients, the change would be felt in small ways first: referral rules, reimbursement lists and the familiar autumn letter announcing next year's premium.
International comparisons are invoked constantly and rarely help. Switzerland spends more than almost anyone and gets results to match, a trade voters keep accepting with visible reluctance.
The proposal lands in a system already under strain. Costs have risen faster than wages for a decade, and patience in households is wearing thin.
Doctors' associations agree on the diagnosis and disagree on the cure. Their counterproposal shifts money toward primary care, slowly, which is precisely why it is hard to pass.
For patients, the change would be felt in small ways first: referral rules, reimbursement lists and the familiar autumn letter announcing next year's premium.